scholarly journals Malignant peritoneal mesothelioma

KYAMC Journal ◽  
2018 ◽  
Vol 8 (2) ◽  
pp. 40-42
Author(s):  
Sayeed Bin Sharif
Keyword(s):  
Early Diagnosis ◽  
Rare Disease ◽  
Incidence Rate ◽  
Malignant Mesothelioma ◽  
Poor Prognosis ◽  
Standard Treatment ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Aggressive Tumor ◽  
Reported Data

Malignant mesothelioma is one of the rare disease. It is an aggressive tumor arising from the mesothelial lining of the pleura or peritoneum. In our country there is no reported data or known incidence rate. It has an association with exposure to asbestos and usually has a poor prognosis. Early diagnosis and establishment of a standard treatment for malignant peritoneal mesothelioma is difficult. We report on a case of malignant peritoneal mesothelioma in a 59-year-old man with huge abdominal swelling, ascites and respiratory distress.KYAMC Journal Vol. 8, No.-2, Jan 2018, Page 40-42

Malignant Peritoneal Mesothelioma

1982 ◽  
Vol 68 (1) ◽  
pp. 91-94 ◽  
Author(s):  
Giovanna Botte ◽  
Saro Oriana ◽  
Ferdinando Preda
Keyword(s):  
Clinical Features ◽  
Malignant Mesothelioma ◽  
Poor Prognosis ◽  
Epidemiologic Studies ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
The Poor ◽  
Diagnostic Difficulties

Eight cases of peritoneal malignant mesothelioma observed at the Istituto Nazionale Tumori of Milan from 1972 to 1978 are reported. The clinical features of the cases clearly point out the diagnostic difficulties, the inadequacy of the treatment and the poor prognosis of this neoplasia. The authors maintain that more complete epidemiologic studies and more adequate therapeutic programs could modify the prognosis for this neoplasm.

Nivolumab for malignant peritoneal mesothelioma

2020 ◽  
Vol 13 (11) ◽  
pp. e237721
Author(s):  
Takaaki Tanaka ◽  
Yosuke Miyamoto ◽  
Atsue Sakai ◽  
Nobukazu Fujimoto
Keyword(s):  
Bowel Obstruction ◽  
Biopsy Specimen ◽  
Poor Prognosis ◽  
Malignant Neoplasm ◽  
Abdominal Distension ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
Massive Ascites ◽  
Shipbuilding Industry ◽  
The Third

Malignant peritoneal mesothelioma (MPeM) is a highly malignant neoplasm of the peritoneum, which carries a poor prognosis. A 70-year-old man, who was employed in the shipbuilding industry and exposed to asbestos for 50 years, was found to have a low-density lesion in the peritoneum around the liver and spleen, associated with multiple mediastinal and parasternal lymphadenopathy. Laparoscopic exploration was performed, and biopsy specimen analysis led to a diagnosis of MPeM. Initial systemic chemotherapy comprising cisplatin and pemetrexed yielded a modest cytoreductive effect. However, 4 months later, the patient presented with abdominal distension and anorexia. CT images revealed massive ascites, bowel obstruction and an enlarged intra-abdominal tumour, which was considered progression of the MPeM. The patient was treated with nivolumab. Bowel obstruction was improved after the first administration, and his sense of abdomen distension completely disappeared after the third administration. This case supports the utility of immunotherapy in MPeM.

Malignant Peritoneal Mesothelioma in a 16-Year-Old Girl: Presentation of a Rare Disease

2012 ◽  
Vol 224 (03) ◽  
pp. 170-173 ◽  
Author(s):  
I. Brecht ◽  
A. Agaimy ◽  
M. Besendörfer ◽  
R. Carbon ◽  
F. Thiel ◽  
...  
Keyword(s):  
Rare Disease ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma

scholarly journals Malignant peritoneal mesothelioma: a disease with difficult early diagnosis.

2020 ◽  
Vol 43 (6) ◽  
pp. 390-393
Author(s):  
J López González ◽  
A Delgado Maroto ◽  
E Navarro Moreno ◽  
E Cuello Entrena ◽  
A Porcel Martín
Keyword(s):  
Early Diagnosis ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma

Resumen El mesotelioma maligno peritoneal es una entidad infrecuente con una gran mortalidad, relacionada con la exposición crónica al asbesto. Suelen presentarse en forma de cuadro clínico de distensión abdominal, ascitis, dolor y pérdida de peso. Su diagnóstico suele realizarse en estadios avanzados de la enfermedad dado el carácter inespecífico de la clínica, por lo que el pronóstico de esta patología es malo a corto plazo. Presentamos el caso de un paciente con mesotelioma peritoneal maligno sin exposiciones crónicas al asbesto, diagnosticado de forma tardía por antecedente de hipertensión portal prehepática.

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 9549-9549
Author(s):  
G. Antonini Cappellini ◽  
A. Borczuk ◽  
H. Kim ◽  
M. Hesdorffer ◽  
R. Taub ◽  
...  
Keyword(s):  
Poor Prognosis ◽  
Molecular Profiling ◽  
Peritoneal Mesothelioma ◽  
Differentially Expressed ◽  
Malignant Peritoneal Mesothelioma ◽  
Histologic Subtype ◽  
Ubiquitin Proteasome Pathway ◽  
Peritoneal Tissue ◽  
Ubiquitin Proteasome ◽  
Proteasome Pathway

9549 Background: Malignant peritoneal mesothelioma (MPM) is an aggressive neoplasm derived from cells lining serosal membranes. The characteristics of the epithelial (E) type MPM are distinct from those of the biphasic and sarcomatous (BS) type tumors. The goal of our study was to examine the molecular basis for this distinction. Methods: We used global molecular profiling with DNA microarrays to identify pathways associated with histologic subtype of 16 MPM tumor specimens acquired from patients entered into pilot multimodality protocols at our Institution. We performed immunohistochemistry on a tissue microarray and quantitative-real time PCR to validate the microarray results. Results: We performed average linkage agglomerative hierarchical clustering using microdissected MPM specimens and normal peritoneal tissue. The tumors segregated into two clades associated with histological subtype, which were distinct from the controls. 476 genes were differentially expressed between E and BS histologic classes (P < .001, with permutation test P value of .001). To identify biologically important differentially expressed genes and pathways, we examined the functional annotation of mesothelioma histologic subtype classifiers using the Pathway Comparison tool of BRB-Array. Among the differentially expressed categories was the ubiquitin-proteasome (UP) pathway, which was upregulated in BS tumors. Cytoxicity experiments by MTS assay indicated that, by the computation of combination indexes of activity, cells derived from BS tumors were exquisitely sensitive to sequential combination regimens containing the proteasome inhibitor (PI) bortezomib and oxaliplatin. The mechanism of this synergistic response, which was not detected in cells of E tumor origin, was apoptosis. Conclusions: Together, our results identify the ubiquitin-proteasome pathway as a biomarker of poor prognosis biphasic and sarcomatous malignant peritoneal mesothelioma tumors and suggest that proteasome inhibitors could increase the effectiveness of cytotoxic chemotherapy in this subset of patients. No significant financial relationships to disclose.

scholarly journals A case of obstructive malignant peritoneal mesothelioma treated with postoperative concomitant Cisplatin and Pemetrexed chemotherapy

2017 ◽  
Author(s):  
Rintaro Yoshida ◽  
Tadashi Koga ◽  
Kiyoshi Kajiyama
Keyword(s):  
Small Intestine ◽  
Bowel Obstruction ◽  
Standard Treatment ◽  
Right Hemicolectomy ◽  
Peritoneal Mesothelioma ◽  
Emission Tomography ◽  
Malignant Peritoneal Mesothelioma ◽  
Positron Emission ◽  
Second Resection ◽  
Satisfactory Life

Malignant peritoneal mesothelioma is a rare disease with no established therapeutic method. A 79-year-old man underwent partial resection of the small intestine and right hemicolectomy for a bowel obstruction due to a mass in the small intestine and a submucosal tumour in the transverse colon. Malignant peritoneal mesothelioma was diagnosed from the excised specimen. After surgery, the patient received the cisplatin and pemetrexed therapy that is the standard treatment for malignant pleural mesothelioma. The progression of the remaining disseminated lesions could be controlled for a year, and the patient could lead a satisfactory life without adverse events. He had a bowel obstruction 12 months after the surgery, and showed increased fluorodeoxyglucose uptake and new sites of high fluorodeoxyglucose uptake. Positron emission tomography-computed tomography was useful as the index of disease progression. Despite a second resection, the patient died 14 months after the first surgery.

scholarly journals Malignant Peritoneum Mesothelioma with Hepatic Involvement: A Single Institution Experience in 5 Patients and Review of the Literature

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Shan-shan Su ◽  
Guo-qi Zheng ◽  
Ya-gang Liu ◽  
Yue-feng Chen ◽  
Zhao-wei Song ◽  
...  
Keyword(s):  
Malignant Mesothelioma ◽  
Asbestos Exposure ◽  
Peritoneal Mesothelioma ◽  
Liver Involvement ◽  
Review Of Literature ◽  
Malignant Peritoneal Mesothelioma ◽  
Single Institution ◽  
Hepatic Involvement ◽  
Computed Tomography Images ◽  
History Of

Malignant peritoneal mesothelioma with invasion of the liver is an invariably fatal disease. We aimed to clarify the characteristics of malignant peritoneal mesothelioma cases with liver involvement. The clinical presentation, computed tomography images, and immunohistochemical and histopathological features of 5 patients with malignant peritoneal mesothelioma and liver involvement were evaluated. The diagnosis was established by imaging and immune profiles of the tumours. A review of 8 cases with primary or invading malignant mesothelioma in liver is presented. All 5 mesothelioma cases were asbestos-related. CT images of malignant peritoneal mesothelioma with the liver involvement typically showed that the lesion grew inside the liver along the capsule and was possibly accompanied by capsule breakthrough and extrahepatic infiltration. The tumours exhibited a common epithelioid appearance in all 5 patients and most cases revealed positive Cal, CK, and MC with negative CEA and HeP. Different from our findings, the review of literature revealed that most malignant mesothelioma of liver was due to primary intrahepatic malignant mesothelioma. Finally, we concluded that the diagnosis of malignant peritoneal mesothelioma cases with liver invasion is reliably achieved by the history of asbestos exposure, the characteristic CT imaging, and immune profiles of the tumours.

scholarly journals Advances in diffuse malignant peritoneal mesothelioma

2011 ◽  
pp. 53-64
Author(s):  
Tristan D. Yan ◽  
Raffit Hassan ◽  
Laura Welch ◽  
Paul H. Sugarbaker
Keyword(s):  
Malignant Mesothelioma ◽  
Asbestos Exposure ◽  
Combined Treatment ◽  
Medical Science ◽  
Great Majority ◽  
Terminal Condition ◽  
Peritoneal Mesothelioma ◽  
Malignant Peritoneal Mesothelioma ◽  
The Past ◽  
Diffuse Malignant Peritoneal Mesothelioma

Malignant mesothelioma is a highly aggressive neoplasm. The incidence of malignant mesothelioma is increasing worldwide. Diffuse malignant peritoneal mesothelioma (DMPM) represents one-fourth of all mesotheliomas. Association of asbestos exposure with DMPM has been observed, especially in males. A great majority of patients present with abdominal pain and distension, caused by accumulation of tumors and ascitic fluid. In the past, DMPM was considered a pre-terminal condition; therefore attracted little attention. Patients invariably died from their disease within a year. Recently, several prospective trials have demonstrated median survival of 40 to 90 months and 5-year survival of 30% to 60% after the combined treatment using cytoreductive surgery and perioperative intraperitoneal chemotherapy. This improvement in survival has prompted new searches into the medical science related to DMPM, a disease previously ignored as uninteresting. This review article focuses on the key advances in the epidemiology, diagnosis, staging, treatments and prognosis of DMPM that have occurred in the past decade.

Sign in / Sign up

Export Citation Format

Share Document